Design Therapeutics FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million

Reuters

Mar 10

Design <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million

Design Therapeutics reported a Q4 net loss of USD 16 million, with R&D expenses of USD 13.43 million. Q4 G&A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&D expenses increased 33% to USD 59.13 million. FY 2025 G&A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2 (Friedreich ataxia) and DT-168 (FECD) are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668306) on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618671704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618671704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618671704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618671704","market":"us","top_or_hot":-1,"title":"Design Therapeutics FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss rose 41% to USD 69.79 million, R&amp;D expenses increased 33% to USD 59.13 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Design Therapeutics reported a Q4 net loss of USD 16 million, with R&amp;D expenses of USD 13.43 million. Q4 G&amp;A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&amp;D expenses increased 33% to USD 59.13 million. FY 2025 G&amp;A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2 (Friedreich ataxia) and DT-168 (FECD) are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668306) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Design Therapeutics FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDesign Therapeutics FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss rose 41% to USD 69.79 million, R&amp;D expenses increased 33% to USD 59.13 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Design Therapeutics reported a Q4 net loss of USD 16 million, with R&amp;D expenses of USD 13.43 million. Q4 G&amp;A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&amp;D expenses increased 33% to USD 59.13 million. FY 2025 G&amp;A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2 (Friedreich ataxia) and DT-168 (FECD) are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668306) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL32LZmj:1","article_id":"2618671704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618671704","pubTimestamp":1773086492,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Design Therapeutics reported a Q4 net loss of USD 16 million, with R&D expenses of USD 13.43 million. Q4 G&A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&D expenses increased 33% to USD 59.13 million. FY 2025 G&A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2  and DT-168  are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","DSGN":"Design Therapeutics, Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4539":"次新股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念"},"translate_title":"Design Therapeutics 2025财年净亏损增长41%至6979万美元，研发费用增长33%至5913万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DSGN":0.9,"NDAQ":0.9},"content_text":"Design Therapeutics FY2025 net loss rose 41% to USD 69.79 million, R&D expenses increased 33% to USD 59.13 million\n    \n\n        Design Therapeutics reported a Q4 net loss of USD 16 million, with R&D expenses of USD 13.43 million. Q4 G&A expenses rose 5% to USD 4.74 million. For FY 2025, net loss widened 41% to USD 69.79 million, while R&D expenses increased 33% to USD 59.13 million. FY 2025 G&A expenses were USD 20.34 million, and cash, cash equivalents and investment securities were USD 219.85 million at year-end, which the company said is expected to fund planned operations into 2029. The company said trials for DT-216P2 (Friedreich ataxia) and DT-168 (FECD) are ongoing, and it expects to begin dosing DM1 patients with DT-818 in H1 2026, with DT-216P2 and DT-168 data anticipated in H2 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9668306) on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}